US FDA approves budesonide extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis

Source: BioSpace.com Area: News According to a report by BioSpace.com, the US Food and Drug Administration has approved UCERIST (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The approved dosing regimen for adult patients is one 9 mg tablet taken orally once daily in the morning for up to 8 weeks.   [Editor's note: Currently, budesonide capsules (Budenofalk or Entocort) are only licensed for Crohn's disease in the UK.]
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news